European Leukemia Trial Registry
Trial: AMLSG 21-13

More Details
Title Dasatinib in patients with newly diagnosed Core-Binding Factor AML
Scientific Title Randomized Phase III Study of Intensive Chemotherapywith or without Dasatinib (Sprycel™) in Adult Patientswith Newly Diagnosed Core-Binding FactorAcute Myeloid Leukemia (CBF-AML)
Short Title AMLSG 21-13
Trialgroup AMLSG Ulm
Type of Trial multicentric, randomized, prospective, open-label, double-group
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age All ages
Status Active
Start of Recruitment 22.07.2014
Leader Döhner, Prof. Dr. med., Hartmut
Contactperson

principal investigator
Döhner, Prof. Dr. med., Hartmut
Tel: +49 (0)731 50045501
Fax: +49 (0)731 50045905
Email: hartmut.doehner@uniklinik-ulm.de

Administrative needs
Paschka, Dr., Peter
Tel: +49 (0)731 500 45757
Fax: +49 (0)731 500 45905
Email: Peter.paschka@uniklinik-ulm.de

Study Centre
Weimann, Stefanie
Tel: +49 (0)731 500 45914
Fax: +49 (0)731 500 45905
Email: Stefanie.weimann@uniklinik-ulm.de

Shortprotocol Shortprotocol
Diagnostics

Cytogenetics
Labor für Zytogenetische und Molekulargenetische Diagnostik, Klinik für Innere Med. III, Universitätsklinikum Ulm
Hämatologie, Hämostaseologie, Onkologie Hannover
Institut für Humangenetik, Medizinische Hochschule Hannover (MHH)

created 31.07.2014 Johannes Kraus
changed 09.11.2015 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org